Replies to post #241870 on Biotech Values

[swampboots]

SBTX: They are shooting miraculous darts, hoping to match their failing candidate with a better one that showed some early promise, without a real theory prompting a reasonable reason for success with their stale candidate.


https://endpts.com/another-biotech-falls-on-hard-times-as-silverback-axes-lead-i-o-candidates-lays-off-more-than-a-fourth-of-staff/

"The company joins the parade of biotechs that have been forced to reevaluate their lead programs and reduce their workforces this quarter, as a bearish market continues to batter the sector."

[DewDiligence]

SBTX—From #msg-168412907 (Apr 2022):

I think SBTX is flailing and there is little reason to think SBT8230 will be an effective agent in treating HBV.

SBTX's BoD agrees, evidently.